Key facts
- Cognito Therapeutics’s last known valuation is $30.0M (Jul 2016).
- It has raised $264.4M across 2 recorded rounds; the latest was Early Stage VC ($10.2M) in Jun 2024.
- Notable investors include MicroVentures, Morningside Group, IAG Capital Partners, Wilson Sonsini Goodrich & Rosati, Starbloom Capital — 11 tracked in total.
- Cognito Therapeutics has filed 3 Form Ds with the SEC since 2022, most recently Jul 2024 ($10.2M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cognito Therapeutics
Funding rounds
2 roundsAbout Cognito Therapeutics
Developer of digital therapeutics designed to treat neurodegenerative disorders by modulating brain activity and targeting underlying disease mechanisms associated with cognitive decline. The company offers therapies that induce specific brain wave oscillations through non-invasive stimulation, modulate neural activity, and activate immune responses in the brain to target amyloid plaques and tau tangles, enabling patients with neurodegenerative disorders to address disease progression and support cognitive function.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 42
- Website
- cognitotx.com/
- Ownership
- Privately Held (backing)
Cognito Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cognito Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cognito Therapeutics in its N-PORT filings yet. We sweep new filings monthly.